BioSpace News Archive

Magenta Therapeutics (Nasdaq: MGTA) today announces that, per the clinical trial protocol for the MGTA-117 Phase 1/2 Dose Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), it has stopped dosing participants at the Cohort 4 dosing level (0.13 mg/kg) and plans to dose additional participants at the Cohort 3 dosing level (0.08 mg/kg).

Global health services company Cigna Corporation (NYSE:CI) announced today that David Cordani, chairman and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 in San Francisco, CA.

Parallel Bio, a biotech company unlocking the human body’s own power to cure disease, today unveiled $4.3 million in seed funding.

Mizuho OSI®, a leading manufacturer of specialty surgical tables and pressure injury abatement solutions has been recognized by The California Council for Excellence as one of only three silver level recipients of the California Awards for Performance Excellence.

Sosei Group Corporation announces its President & CEO Chris Cargill will present at the 41st Annual J.P. Morgan Healthcare Conference.

Verona Pharma plc, announces positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.

Scorpion Biological Services announced it has changed its name to Scorpius BioManufacturing reflecting the company’s recently expanded manufacturing capabilities and the grand opening of its new biomanufacturing facility in San Antonio in October.

Mainz Biomed NV announced the first patient has been enrolled in eAArly DETECT, Mainz’s U.S. extension of ColoFuture, its European feasibility study evaluating the integration of a portfolio of novel gene expression biomarkers into ColoAlert.

Calibre Scientific is pleased to announce the acquisition of Carvalhaes, a Brazilian distributor of laboratory consumables and scientific equipment.

SURGLASSES announced that Caduceus S AR Spine Navigation System has received 510 clearance from the U.S. Food and Drug Administration and is ready to launch its products into the US market in the first quarter of 2023.